Carlyle Group’s Jasper Therapeutics JSPR Stock Holding History

Carlyle Group’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$449K	Hold	1,066,189	–	–	﹤0.01%	17
2026 Q1	$934K	Hold	1,066,189	–	–	0.01%	14
2025 Q4	$1.94M	Hold	1,066,189	–	–	0.01%	11
2025 Q3	$2.53M	Hold	1,066,189	–	–	0.06%	9
2025 Q2	$5.92M	Hold	1,066,189	–	–	0.12%	8
2025 Q1	$4.58M	Hold	1,066,189	–	–	0.12%	11
2024 Q4	$22.7M	Hold	1,066,189	–	–	0.55%	6
2024 Q3	$19.9M	Hold	1,066,189	–	–	2.08%	7
2024 Q2	$24.2M	Hold	1,066,189	–	–	2.3%	9
2024 Q1	$31.3M	Buy	1,066,189 +190,000	+22%	+$3.37M	1.97%	8
2023 Q4	$6.67M	Hold	876,189	–	–	0.32%	15
2023 Q3	$6.05M	Hold	876,189	–	–	0.26%	17
2023 Q2	$11.8M	Hold	876,189	–	–	0.42%	14
2023 Q1	$15.8M	Buy	+876,189	New	+$16.2M	0.47%	12

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Carlyle Group's JSPR Position: Q2 2026 in Review

Carlyle Group held its Jasper Therapeutics (JSPR) position steady in Q2 2026 at 1,066,189 shares worth $449K. The position accounts for ﹤0.01% of the portfolio, ranked #17.

Carlyle Group first reported a position in JSPR in Q1 2023 and has held it in 14 quarters since. The position peaked at $31.3M in Q1 2024. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

Carlyle Group held 1,066,189 shares of Jasper Therapeutics worth $449K as of Q2 2026.
Carlyle Group left its Jasper Therapeutics share count unchanged in Q2 2026.
Jasper Therapeutics made up ﹤0.01% of Carlyle Group's portfolio in Q2 2026, its #17 holding.
Carlyle Group first reported a position in Jasper Therapeutics in Q1 2023 and has held it in 14 quarters since.
Carlyle Group's Jasper Therapeutics position peaked at $31.3M in Q1 2024.
45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Carlyle Group's 13F filing for Q2 2026, filed 7 Aug 2026.